A Study to See How a New Compound, Trontinemab Affects the Body and Whether Immune Signals Triggered by it Affect How Other Medicines are Processed

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526756-31-00

Enrollment

Registered

2026-09-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Not Applicable

None listed

Sex/Gender

Male

Age

18 Years to 64 Years

None listed

Source: EU CTIS · Data processed: Sep 5, 2026